StockMacro
Menu

SpyGlass Pharma

$30.43 +48% in 6 monthsMarket cap $1.0B

SGP on XNAS, Health Care, SpyGlass Pharma, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 46% in six months, but the company lost $70.5M over 12 months.

  • GoodInstitutional holders rose 33% to 68 filers last quarter
  • BadFree cash outflow of $59.2M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
65
Website
spyglasspharma.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 25 Mar 2027 (an estimate: a year ago it reported on 26 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $24.3M.
Quarter to 31 Mar 2025: revenue –, net income -$8.8MQuarter to 30 Jun 2025: revenue –, net income -$8.7MQuarter to 30 Sep 2025: revenue –, net income -$9.8MQuarter to 31 Dec 2025: revenue –, net income -$12.6MQuarter to 31 Mar 2026: revenue –, net income -$13.8MQuarter to 30 Jun 2026: revenue –, net income -$19.9MQuarter to 30 Sep 2026: revenue –, net income -$24.3M
31 Mar 2025RevenueNet incomeNet losstallest bar $24.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$24.3M
30 Jun 2026–-$19.9M
31 Mar 2026–-$13.8M
31 Dec 2025–-$12.6M
30 Sep 2025–-$9.8M
30 Jun 2025–-$8.7M
31 Mar 2025–-$8.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$70.5M –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$59.2M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $208.7M $106.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$208.7M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.29
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.8 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
SpyGlass PharmaSGP (this company) $1.0Bloss–––
AlphatecATEC $1.0Bloss1.2+15%-10.3%
Integra LifeSciencesIART $1.0B79.20.62+0.8%0.8%
iRadimedIRMD $1.0B43.211.6+11%26.8%
Si-BoneSIBN $1.1Bloss4.9+14%-6.2%
ArtivionAORT $886.0Mloss1.8+14%-3.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$32K

bought $32K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+33%

68 13F filers vs 51

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

79%

26.4M shares held by 13F filers (30 Sep 2026) of 33.5M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.5%

1.2M shares sold short (30 Oct 2026) of 33.5M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

12.1

1.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.2%

1.2M shares sold short in the report before, 1.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

78%

78% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

12

12 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

12×

12 articles in the last 7 days; its usual week has 1.

Price $30.43 on 20 Nov 2026, +15% over 12 months (12-month range $17.56 to $38.37)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $98.9M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Capital spending per quarter. Capital spending $2.5M in the latest quarter, +1520% on a year earlier.
Institutional holders (13F filers). 68 13F filers reported holding it in the latest 13F quarter, +100% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
13 Feb 20268-K and other filingsDirector or officer change
12 Feb 2026Sharp changeClustered insider buying: clustered insider buying (6 independent filers, 6 filing(s) in 30 days, value_usd total 98.8M)
9 Feb 20268-K and other filingsDirector or officer change
9 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
16 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
5 Jun 20258-K and other filingsPrivate placement of securities (Form D)
11 Jul 20238-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Feb 2026: $98.8M published
Month from 1 Nov 2026: $32K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Oct 2025: 1 published
Capital spending per quarter
Quarter ended 31 Mar 2025: $164K; public on 15 May 2026
Quarter ended 30 Jun 2025: $52K; public on 7 Aug 2026
Quarter ended 30 Sep 2025: $152K; public on 13 Nov 2026
Quarter ended 31 Dec 2025: $421K; public on 27 Mar 2026
Quarter ended 31 Mar 2026: $676K, +312% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $1.9M, +3615% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.5M, +1520% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Mar 2026 report: 34; public on 15 May 2026
30 Jun 2026 report: 51; public on 14 Aug 2026
30 Sep 2026 report: 68; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is stockholders' equity at period end at $210.4M (30 Sep 2026), 425% below its normal quarter of -$64.7M; higher than 78% of its own history.
  • Insider net buying (open market): Insiders bought a net $98.9M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Capital spending per quarter: Capital spending $2.5M in the latest quarter, +1520% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 16 insider trades

Last 90 days: no sales; 1 purchase, $32K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Ra Capital Management, L.P. and 4 othersDirector, 10% ownerBuy1,000$32.43$32KForm 4
11 Feb 2026Geoffrey B PardoDirectorBuy312,500$16.00$5.0MForm 4
11 Feb 2026Bilal Arshad KhanDirectorBuy135,000$16.00$2.2MForm 4
11 Feb 2026Nea 17 GP, LLC and 2 others10% ownerBuy937,500$16.00$15.0MForm 4
11 Feb 2026RA Capital Healthcare Fund LP and 4 othersDirector, 10% ownerBuy3,690,000$16.00$59.0MForm 4
11 Feb 2026Paul Edward Walker10% ownerBuy937,500$16.00$15.0MForm 4
10 Feb 2026Vensana Capital I GP, LLC and 3 others10% ownerBuy165,000$16.00$2.6MForm 4

68 institutions reported shares at the end of Q3 2026, 79% of the shares outstanding; 20 opened a position, 3 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Ra Capital Management, L.P.8.0M24.0%$208.5MNo change
NEA Management Company, LLC7.4M22.1%$192.2MNo change
Sands Capital Alternatives, LLC2.5M7.47%$65.0MNo change
Samsara Biocapital, LLC2.1M6.31%$54.9MNo change
JPMorgan Chase & Co1.0M3.00%$25.5M+374K+59%
T. Rowe Price Associates Inc926K2.77%+252K+37%
Vanguard Capital Management LLC661K1.97%$17.2M+226K+52%
Vestal Point Capital, LP640K1.91%$16.6M-30K-4.5%
BlackRock, Inc.630K1.88%$16.4M-81K-11%
Aberdeen Group plc507K1.51%$13.2M+13K+2.7%

Company events

All 8 company events

In 12 months: 2 share registrations, 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Feb 2026Director or officer change8-K
9 Feb 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
29 Jan 2026Registered new securities for sale (S-1)S-1/A
16 Jan 2026Registered new securities for sale (S-1)S-1
5 Jun 2025Private placement of securities (Form D)$75.0M sold of $75.0M offeredD
11 Jul 2023Private placement of securities (Form D)$40.0M sold of $90.0M offeredD
5 Jan 2021Private placement of securities (Form D)$13.7M sold of $37.5M offeredD
5 Jun 2019Private placement of securities (Form D)$6.0M sold of $6.0M offeredD

The 5 newest of 76 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 18 Nov 2026Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 1,000 shares of SGP ($32,430)

  2. 13 Feb 2026Filings record

    Director or officer change

  3. 12 Feb 2026Insiders change

    had 6 insiders buy $98.8M of its shares on the open market within 30 days (6 filings).

    Who bought: Walker Paul Edward, Khan Bilal Arshad, Pardo Geoffrey B.

    See the evidence (6 source records)
    Independent buyers
    6
    Purchase filings (Form 4, code P)
    6
    Total bought
    $98.8M
    Window
    13 Jan 2026 to 12 Feb 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  4. 12 Feb 2026Insiders record

    Pardo Geoffrey B (director) bought 312,500 shares of SGP ($5.0M) (dated 11 Feb 2026)

  5. 12 Feb 2026Insiders record

    SANDELL SCOTT D (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  6. 12 Feb 2026Insiders record

    Florence Anthony A. Jr. (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  7. 12 Feb 2026Insiders record

    Mathers Edward T (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  8. 12 Feb 2026Insiders record

    Chang Carmen (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  9. 12 Feb 2026Insiders record

    Behbahani Ali (director) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  10. 12 Feb 2026Insiders record

    Khan Bilal Arshad (director) bought 135,000 shares of SGP ($2.2M) (dated 11 Feb 2026)

  11. 12 Feb 2026Insiders record

    NEA 17 GP, LLC (ten percent owner) and 2 other(s) bought 937,500 shares of SGP ($15.0M) (dated 11 Feb 2026)

  12. 12 Feb 2026Insiders record

    RA Capital Healthcare Fund LP (director) and 4 other(s) bought 3,690,000 shares of SGP ($59.0M) (dated 11 Feb 2026)

  13. 12 Feb 2026Insiders record

    BASKETT FOREST (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  14. 12 Feb 2026Insiders record

    Walker Paul Edward (ten percent owner) bought 937,500 shares of SGP ($15.0M) (dated 11 Feb 2026)

  15. 12 Feb 2026Insiders record

    Yang Rick (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  16. 12 Feb 2026Insiders record

    Makhzoumi Mohamad (ten percent owner) bought 937,500 shares of SGP [same transaction as an earlier filing] (dated 11 Feb 2026)

  17. 11 Feb 2026Insiders record

    Nielsen Kirk G. (director) bought 165,000 shares of SGP [same transaction as an earlier filing] (dated 10 Feb 2026)

  18. 11 Feb 2026Insiders record

    Vensana Capital I GP, LLC (ten percent owner) and 3 other(s) bought 165,000 shares of SGP ($2.6M) (dated 10 Feb 2026)

  19. 9 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 9 Feb 2026Filings record

    Director or officer change

  21. 29 Jan 2026Filings record

    Registered new securities for sale (S-1)

  22. 16 Jan 2026Filings record

    Registered new securities for sale (S-1)

  23. 5 Jun 2025Filings record

    Private placement of securities (Form D)

  24. 11 Jul 2023Filings record

    Private placement of securities (Form D)

  25. 5 Jan 2021Filings record

    Private placement of securities (Form D)

  26. 5 Jun 2019Filings record

    Private placement of securities (Form D)

Not listed: 12 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001778922
Ticker
SGP
Domain
spyglasspharma.com
Employer name
SpyGlass Pharma, Inc. (1 unverified)
Fein
83-3044245 (1 unverified)
Hq location
CA|IRVINE|92618 (1 unverified)
Name
SpyGlass Ophthalmics, Inc., SpyGlass Pharma, Inc., SpyGlassPharma, Inc.
  • DOL H-1B labor condition applications and PERM certifications10 data points22 Jul 2024 to 1 Jul 2025
  • SEC Form 13F institutional holdings27 data points31 Mar 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)20 records5 Jun 2019 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)91 data points31 Dec 2023 to 2 Nov 2026
  • SEC Form 4 insider transactions16 records, 12 data points10 Feb 2026 to 18 Nov 2026
  • FINRA short interest (twice monthly)53 data points13 Feb 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)400 data points6 Feb 2026 to 20 Nov 2026